文献速递肾移植

奥密克戎变异株时代肾移植中COVID-19相关问题:ERA Descartes工作组评论

Issues regarding COVID-19 in kidney transplantation in the ERA of the Omicron variant: a commentary by the ERA Descartes Working Group.
PubMed 文献 · Nephrol Dial Transplant · 2022-01-01

ERA Descartes工作组针对奥密克戎变异株时代肾移植受者COVID-19的日常临床实践问题发表评论,涉及重症风险与突破性感染、免疫抑制管理、被动免疫与抗病毒药物、药物相互作用、SARS-CoV-2阳性供者安全标准、T细胞清除剂诱导治疗及防护实践推荐。

要点

  • 奥密克戎变异株带来新挑战,疫苗接种及新防治策略引发肾移植受者多个新问题。
  • 工作组讨论重症风险、突破性感染、免疫抑制管理及门诊患者抗病毒治疗。
  • 涉及药物相互作用、SARS-CoV-2阳性供者安全标准及T细胞清除剂诱导治疗。

核心结论

  • 工作组针对肾移植受者及供者评估的多个临床问题提出讨论,涉及重症风险、免疫抑制管理、被动免疫、抗病毒药物、药物相互作用、阳性供者安全标准、T细胞清除剂诱导治疗及防护实践。

研究设计与样本

  • 欧洲肾脏协会(ERA)Descartes工作组(Developing Education Science and Care for Renal Transplantation in European States)发表的评论/特别报告。

主要发现

  • 奥密克戎变异株已成为全球SARS-CoV-2优势株,带来防控新挑战。
  • 过去12-18个月疫苗接种政策广泛实施及COVID-19新预防和治疗策略发展,引发肾移植受者多个新问题。
  • 工作组针对肾移植受者日常临床实践及 deceased 和活体供者评估提出若干问题,包括重症风险、突破性感染、免疫抑制管理、被动免疫、抗病毒药物、药物相互作用、阳性供者安全标准、T细胞清除剂诱导治疗及防护实践。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Omicron variant, which has become the dominant strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, brings new challenges to preventing and controlling the infection. Moreover, the widespread implementation of vaccination policies before and after transplantation, and the development of new prophylactic and treatment strategies for coronavirus disease 2019 (COVID-19) over the past 12-18 months, has raised several new issues concerning kidney transplant recipients. In this special report, the ERA DESCARTES (Developing Education Science and Care for Renal Transplantation in European States) Working Group addresses several questions related to everyday clinical practice concerning kidney transplant recipients and to the assessment of deceased and live kidney donors: what is the current risk of severe disease and of breakthrough infection, the optimal management of immunosuppression in kidney transplant recipients with COVID-19, the role of passive immunization and the efficacy of antiviral drugs in ambulatory patients, the management of drug-to-drug interactions, safety criteria for the use of SARS-CoV-2-positive donors, issues related to the use of T cell depleting agents as induction treatment, and current recommendations for shielding practices.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Gandolfini I, Crespo M, Hellemans R, et al. Issues regarding COVID-19 in kidney transplantation in the ERA of the Omicron variant: a commentary by the ERA Descartes Working Group. Nephrol Dial Transplant. 2022. PMID: 35746885. doi:10.1093/ndt/gfac203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。